Evicenter
MarkdownMedical informationP&T meetings
Envudeucitinib (ESK-001)

Moderate-to-severe plaque psoriasis

Also known as FTP-637
Manufacturer
Alumis
Launch
Not announced
Last updated
277 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Expected outcomes of therapy

7 evidence topics · 6 sources

Summary
  • Treatment goals: the EuroGuiDerm-adapted German S3 guideline (Nast et al.) names complete clearance as the fundamental goal of therapy and states that this goal is “not realistically achievable in all patients at this time”. A PASI 75 response is the minimum target at the end of the induction period, and PASI 90, an absolute PASI <2, or DLQI ≤ 1 is the desired goal. Goals are checked after 10 to 12 weeks for treatments with a fast onset of action and after 16 to 24 weeks for treatments with a slower onset, time frames that “may not always include the time of maximum therapeutic effect”.
  • Body surface area targets: Armstrong et al. set the acceptable response at 3 months as BSA 3% or less or BSA improvement of 75% or more from baseline, and the target response as BSA 1% or less at 3 months and at every 6-month maintenance evaluation.
  • Time to response: in an analysis of forty-five trials, the IL-17 inhibitors bimekizumab, ixekizumab, brodalumab, and secukinumab 300 mg were estimated to reach onset of PASI 90 response at approximately 6 to 8 weeks, the IL-23 inhibitors risankizumab and guselkumab at approximately 9–10 weeks, and the IL-12/23 inhibitor at 11–12 weeks; onset could not be estimated for tildrakizumab or for JAK and PDE4 inhibitors.
  • Quality of life by depth of response: in 16-week pooled data, the estimated proportions achieving DLQI 0/1 were 93.0% with PASI 100, 89.3% with a 95% PASI improvement, and 83.8% with a 90% PASI improvement, and the proportions with no itching (P-SIM = 0) were 61.7%, 50.8%, and 39.8%.
  • Maintenance with continuous biologic therapy: in LIMMitless, 661 of 897 enrolled participants completed the study, and at week 304, 86.0% achieved PASI 90, 54.2% PASI 100, 84.7% sPGA 0/1, and 76.3% DLQI 0/1 with risankizumab (modified nonresponder imputation). With secukinumab 300 mg, 168 participants entered the extension and 126 completed year 5; PASI 75/90/100 responses were 88.9%, 68.5%, and 43.8% at year 1 and 88.5%, 66.4%, and 41% at year 5, and DLQI 0/1 responses were 72.7% and 65.5%.
Time to response and timing of the treatment goal assessment